MedTrace Logo

Non-Significant Risk Study of Sebacia Microparticles in the Treatment of Facial Acne Vulgaris

NCT03303170 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 168

Last updated 2019-10-14

No results posted yet for this study

Summary

Prospective, randomized, controlled, parallel group clinical study with blinded assessment evaluating Sebacia Microparticles (SM) with Nd:Yag laser in facial inflammatory acne vulgaris

Conditions

  • Acne Vulgaris

Interventions

DEVICE

Sebacia Microparticles

Topical microparticle suspension

DEVICE

Nd:Yag Laser

Laser delivering 1064 nm wavelength light

Sponsors & Collaborators

  • Sebacia, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-25
Primary Completion
2018-04-10
Completion
2018-04-10
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03303170 on ClinicalTrials.gov